The FDA issued draft guidance intended to streamline regulatory development of personalized gene therapies built on individualized genome editing. The draft, “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management” (FDA-2026-D-11783), proposes a framework for how sponsors can submit biologics license applications for patient-specific editing products. A key element is the concept of the Individualized Feature Space (IFS), describing pre-defined allowable variation limits for genome-edited components—such as gRNA spacer sequences—within a single BLA. Under the IFS approach, therapies may vary from patient to patient without requiring additional clinical trials, if the edits fall within defined categories that yield the same intended editing outcome. The guidance was released amid investor attention on gene editing catalysts following data from the ESGCT Annual Congress in Hamburg. FDA indicated it is soliciting public comment through November 27, enabling sponsors to adapt trial and CMC plans ahead of eventual finalization. Equity analysts characterized the draft as de-risking for gene editing companies by adding constructiveness around regulatory expectations for individualized products.